InterMune

InterMune is a leading biotechnology organization dedicated to embodying integrity, passion, accountability, creativity, and teamwork. InterMune strives to bring innovative treatments and renewed hope to patients and families worldwide.

With a strong focus on research, development, and commercialization, InterMune specializes in innovative therapies within pulmonology and orphan fibrotic diseases. This includes a dedicated effort to combat idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, and ultimately fatal lung disease. InterMune markets Pirfenidone, the only approved medicine for IPF, as Esbriet® in the EU and Canada, and is actively pursuing regulatory registration in the United States through a Phase 3 clinical trial.

InterMune is committed to improving patient outcomes and advancing the field of pulmonology through cutting-edge research and therapeutic solutions. We invite the management team at InterMune to create a customized and exclusive company showcase and product listing on our platform to further enhance visibility and commercial opportunities.